Kyprolis® (carfilzomib) – Expanded indication
June 30, 2022 - The FDA approved Amgen’s Kyprolis (carfilzomib), in combination with Sarclisa® (isatuximab-irfc) and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
Top